The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA).
 
Lionel Aurelien Kankeu Fonkoua
No Relationships to Disclose
 
Sakti Chakrabarti
No Relationships to Disclose
 
Mohamad Bassam Sonbol
No Relationships to Disclose
 
Pashtoon Murtaza Kasi
Consulting or Advisory Role - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst)
 
Jason Scott Starr
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene
 
Alex J Liu
No Relationships to Disclose
 
Melanie C. Bois
No Relationships to Disclose
 
Henry C. Pitot
No Relationships to Disclose
 
Helen J. Ross
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Spectrum Pharmaceuticals (Inst); Spectrum Pharmaceuticals (Inst); Spectrum Pharmaceuticals (Inst); Spectrum Pharmaceuticals (Inst)
 
Tsung-Teh Wu
No Relationships to Disclose
 
Rondell P. Graham
No Relationships to Disclose
 
Svetomir Markovic
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Seagen; Seagen; Seagen; Seagen
 
Haidong Dong
No Relationships to Disclose
 
Harry H. Yoon
Honoraria - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Macrogenics; Macrogenics; Macrogenics; Macrogenics; Merck; Merck; Merck; Merck
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly